Evidence2Practice Ontario



Our EMR-integrated heart failure tool for TELUS PS Suite, OSCAR Pro, and Accuro QHR supports primary care by giving them easier access to the information they need at the point of care.

Features include:

Investigations into heart failure diagnosis

Evidence-based guidance to assist clinicians with identifying, tracking, and supporting at-risk patients

Medication plan management

Easy access to information for clinicians to reference, with picklists to facilitate appropriate medication selection, built-in notification flags to have medication changed if the patient's condition is worsening, and more

Modular approach for adaptive workflows

Users can fill out certain parts of the tool to gather information during the patient visit as opposed to opening an entire form to fill out a specific part

					Last Complet	ed: 08/14/2023
Health promo	ion					
Reviewed imm	unizations 🕕					
Reviewed salt	ifluid vigilance 🕕					
	i daily weight monitoring 🕕					
	at physical activity					
	anced care planning 🕕					
	portive or palliative care needs id	entified				
	therence and response					
ledication adhere						
	elping? O Yes O No					
	ienced? O Yes O No					
Severity of side ef	fects Select V					
Medication pla	n					
	cation reference table to view py (recommended for patients w			Balaat		
Medication	py (recommended for patients v	vinth reduced ejectio	n maction (<= 40%): Select	•	
Select media	Medication Modu	le	cop	y from prior ck	ar /ast done: 20	13-09-18
Select media 📈			cop	y from prior ck	last done: 20	13-00-18
نہ Select media Select media	Monitoring - adherence and re	sponse		y from prior cle	Nar last done: 20	13-09-18
Select media Select media A		sponse Medication adherend			iast done: 20	23-09-18
نہ Select media Select media	Monitoring - adherence and re Current medications EMPAGLIFLOZIN 25MG 0	Sponse Medication adherent Is medication helping	17 () Yes	No	Nar Jast done 20	13-00-18
Select media Select media A	Monitoring - adherence and re Current medications	sponse Medication adherend			ar last done 20	23-06-18
Select media Select media A	Monitoring vadherence and re Current medications EMPAGUIFLOZIN 25MG 0 BID	sponse Medication adherent Is medication helping Side effects	a? Yes Yes	No	ar Jast done 20	23.00-18
Select media Select media A	Meetforting - adherence and re- Current medications EMPAGLIFLOZIN 25MG 0 BID DIGOXIN 0 13MG 0 OD	Medication adherent Is medication helping Side effects experienced?	ar 17 Ves Ves	No	ar iast done 20	23.00-18
Select media Select media A	Monitoring - authorence and re- Current medications EMPAGUIFLOZIN 25MG 0 BID DISOXIN 0 13MG 0 0D Classifulple Therapy	Medication adheren Is medication helping Side effects experienced? Severity of side effect	ar g? Ves O Yes 35 Select	No	ar last done 20	23.00-18
Select media Select media A	Monitori kg c achievence and re Current medications EMPAGLIFLOZIN 25MG 0 BID DIGOXIN 0 13MG 0 00 Okasit upte Thereapy ACEI or ARB or ARNs indicated	Medication adherent Is medication helping Side effects experienced?	ar 17 Ves Ves	No	Nf leaf done 20	23.00-18
Select media Select media A	Monitoring - authorence and re- Current medications EMPAGUIFLOZIN 25MG 0 BID DISOXIN 0 13MG 0 0D Classifulple Therapy	Medication adheren Is medication helping Side effects experienced? Severity of side effect	ar g? Ves O Yes 35 Select	No	Nf leaf done 20	25.00-18
Select media Select media A	Monitori kg c achievence and re Current medications EMPAGLIFLOZIN 25MG 0 BID DIGOXIN 0 13MG 0 00 Okasit upte Thereapy ACEI or ARB or ARNs indicated	Approach Medication eitherenn Is medication heipin Side effects experienced? Seventy of side effect Ves Yes	zrYesYYesYYSYYYSYYYSYYYSYYSYYSYYSYYYSYYYSYYYSYYYSYYYSYYYSYYYSYYYSYYYSYYYSYYYSYYYSYYYSYYYSYYYSYYYSYYYSYYYYSYYYYSYYYY	No	WT last done 20	3.00-18
Select media Select media A	Meetidorage a Biference a not pre Current medications Exemple 10, 2000 2504 0 00 DIGOXIN 0 13M/0 0 00 Country fet Thereary ACE or ARB or ARN indicated Eleta Biocker indicated. Internationational Receptor Artilog	Medication adherem Is medication heiping Side effects experienced? Sevenity of side effect Ores Ores Ores const (MRA)	ar arYes ⊚ Yes 33 Select ⊚ No ⊚ No	© No © No	WT Jeat done 20	
Select media Select media A	Membring - efference and re Current medications Diseased of the Control of the Disease of the Control of the Control of the Control of the Disease of the Control of the Control of the Control of the Disease of the Control of the Control of the Control of the Disease of the Control of the Control of the Control of the Control of the Disease of the Control of the Co	Medication adherem Is medication heiping Side effects experienced? Severity of side effect Vos Vos nonist (MRA) inhibitor (SGLT2)	27 Ves 27 Yes 38 Select No No Yes Yes	○ No ○ No	W lead done 20	C.00-18
Select media Select media A	Nonlighing withermost and ref Current medications (NMPACIFLOZIN 25443 0) (DOXIN 0 13MG 0 00) Construction (Stand 0 00) Construction (Stand 0 00) Construction (Stand 0 00) Construction (Stand 0 00) Microsoft (Stand 0 00) Construction (Stand 0 00) Constr	Medication adherem Is medication heiping Side effects experienced? Severity of side effect Vos Vos nonist (MRA) inhibitor (SGLT2)	27 Ves 27 Yes 38 Select No No Yes Yes	© No © No © No © No		
Select media Select media A	Networking editerrots and ref Carent indicators (IntrAcULICON 25MO E) DOGKIN 1 SMO E DO DOGKIN 1 SMO E DO DO DOGKIN 1 SMO E DO DOGKIN 1 SMO E DO DO DO DO SMO E DO DO DO DO SMO E DO DO DO DO SMO E DO DO DO DO SMO E DO DO DO DO DO DO DO DO DO DO DO DO DO D	Alexandre Medication adheren Is medication helpin Side effects argenerocod? Severity of side effect Vos Vos vos nonist (MRA) Innibitor (SGLT2) producation reference to	27 (Yes 29 (Yes 38 Select No No (Yes (Yes (Yes (Yes (Yes (Yes) (Yes	© No © No © No © No	86	

Medication modules in Accuro QHR and OSCAR Pro

HF w/ Reduced Ejection Fraction	Assessment Medication N		Management	Patient Care Plan &	Resources	Generate Note fo	Generate Note for Today	
Update □ Suspected HF □ HF w/rEF (≤ 40%)	HF w/mrEF (41-49%)	HF w/pEF	(≥50%) □ HF w	v/recovered EF (>40%)	Risk Reviewed	Filter Imaging R	leports	
Usage analytics Feedback New version available Init Visit Q050A:								

Heart failure toolbar in TELUS PS Suite

Evidence2Practice Ontario (E2P) is working with partners in primary and acute care to design a suite of digital solutions and implementation supports that seamlessly integrate up-to-date and relevant evidence and quality standards into front-line clinical systems. We will be rolling out additional tools in a staged approach in different EMRs for anxiety disorders and depression in adults, prediabetes and diabetes, and chronic obstructive pulmonary disease. To find out when tools are made available for your EMR, sign up below to be notified!

Services available

- Change management support for installation & use in EMR
- Academic detailing: 1:1 discussions with a clinical pharmacist

Scan the QR code or visit <u>www.E2P.ca</u> to sign up and get notifications when new

Stay up to date

tools are available for your EMR



Accessible. Actionable. Adaptable.

E2P brings together multi-disciplinary, cross-sector expertise under the joint leadership of the <u>Centre for Effective Practice</u>, eHealth <u>Centre of Excellence</u>, and <u>North York General</u> <u>Hospital</u>. Funding and strategic guidance for E2P is provided by Ontario Health in support of Ontario's Digital First for Health Strategy.





